Spectrum Effect Appoints John Saw to Its Board of Directors
Spectrum Effect™, a pioneer in RF spectrum analytics, today announced that John Saw, CTO of Sprint, was appointed to the company’s Board of Directors. Saw will serve as an independent director, joining current board members Scot Jarvis, Gary Sledge, and Bruce Brda.
John Saw, Ph.D., is Chief Technology Officer at Sprint, responsible for technology development, network planning, engineering, deployment and service assurance of the Sprint network. Prior to this he was Chief Network Officer. Saw has more than 20 years of wireless industry experience. Before Sprint’s acquisition of Clearwire, he was CTO of Clearwire Corp where he had the vision to accumulate a vast portfolio of mid-band spectrum that is ideally suited for 5G NR. He joined Clearwire as its second employee in 2003 and was instrumental in scaling the company’s technical expertise and organization.
"We are delighted to have John join our board,” commented Spectrum Effect Chairman, Scot Jarvis. “John is one of the most highly-regarded leaders in the wireless industry and a proven visionary. Simply put, he will be an invaluable addition to our Board. We look forward to his contributions as we are now entering a rapid growth stage with Spectrum Effect.”
“John brings a wealth of expertise in emerging technologies including 5G NR, and a deep understanding of the needs of mobile operators that will help guide the future direction of our company,” remarked Spectrum Effect CEO, Charles Immendorf. “We welcome John to the Spectrum Effect team.”
“Maximizing spectrum capabilities is undoubtedly one of the most pressing challenges for mobile operators today, and Spectrum Effect is uniquely positioned to disrupt the industry with its innovative spectrum analytics solution, Spectrum-NET,” said John Saw, CTO of Sprint. “This is an exciting time to join the Board of Directors and I look forward to helping the company realize its significant opportunities ahead.”
About Spectrum Effect
Spectrum Effect was founded by the wireless industry veterans behind Eden Rock Communications (SON leader acquired by a tier-1 OEM) with technologies incubated in advanced research projects with the United States Department of Defense and the Office of Naval Research. Spectrum Effect has pioneered a completely new and novel approach for mobile operators to mitigate harmful anomalous interference through innovative machine learning based analytics of mobile network data. Our revolutionary solution, Spectrum-NET, automatically detects, characterizes, classifies, aggregates, locates, predicts and measures the impact of anomalous interference from external, PIM, RAN generated and tropospheric ducting sources. Protected by numerous patents, Spectrum-NET operates seamlessly across multi-vendor UMTS, LTE and (future) 5G NR networks on a continual basis without any need for external probes. With Spectrum-NET, operators across the globe are now rapidly addressing anomalous interference events, improving network KPIs, deploying their field assets with surgical precision and enhancing their customers’ quality of experience.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190710005006/en/
Contact information
Cara Mormino
+1 847 243 3000
cara@spectrumeffect.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom